Dra. Lucia Elizabeth Peraza Meza

https://t.co/raVb2h96Pp

Bempedoic Acid Shows Promise in Reducing Major CV Events in High-Risk Primary Prevention Patients - American College of Cardiology Bempedoic Acid Shows Promise in Reducing Major CV Events in High-Risk Primary Prevention Patients Jun 27, 2023 ACC News Story Font Size A A A Bempedoic acid was associated with reduced major adverse cardiovascular events (MACE) in statin-intolerant primary prevention patients at high cardiovascular....

En actualización continua

La actualización médica es un deber

The classification of mitral valve transcatheter edge-to-edge repair patients into heart failure with reduced ejection fraction-secondary mitral regurgitation stages according to extramitral cardiac involvement provides prognostic value in terms of postinterventional survival and symptomatic improvement.

Learn more in : https://bit.ly/3IaUE1n

This week is Congenital Heart Defect Awareness Week ❤️

is the most common type of birth defect. Nearly 1 out of 100 babies are born with some sort of structural heart defect. Share these resources with your patients and educate them about their condition and the importance of receiving lifelong specialized heart care and monitoring. bit.ly/3RLGCpU

https://www.diariodesevilla.es/sevilla/Realidad-virtual-corazon-ninos-Virgen-Rocio_0_1766224366.amp.html

Realidad virtual para entrenar a niños intervenidos de corazón en el Virgen del Rocío Andalucía pone en marcha un proyecto piloto a través de una empresa de la región para que los pacientes de Cardiología Pediátrica del Hospital Infantil puedan realizar ejercicio desde casa Corazones a punto en el Hospital Infantil del Virgen del Rocío Del mar al espacio desde las consultas de ...

The ACC's newest Expert Consensus Decision Pathway aims to provide structure around the rapid "evaluation and disposition of acute " in patients presenting to the emergency department for a possible acute coronary syndrome (ACS).

Get a recap from this month's article: bit.ly/3hOCkQC

Direct oral anticoagulants (DOACs) are commonly used for the prevention of thrombosis in several cardiovascular contexts.

In several clinical scenarios, the DOAC dose is reduced. The article on "DOACs: Practical Considerations" briefly summarizes the common regimens, appropriate use and uncertain circumstances related to dose-reduced DOACs.

Read the full article here: bit.ly/3geM5aE

https://youtu.be/aL8wZeyR2oU

¿Pasa el futuro del control lipídico por el control de la Lp(a)? M.ª Rosa Fernández Olmo y Enrique Santas Olmeda inauguran el ciclo ‘Reaprendiendo de lípidos’, enfocado en la terapia lipídica, comentando las característica...

trial: screening using conventional smartphones more than doubles the detection and treatment rate in older people compared to routine screening.

trial: allopurinol has failed to reduce the primary endpoint of nonfatal myocardial infarction, nonfatal stroke or death in patients with ischaemic heart disease.

You cannot miss this one: check out the new 2022 guidelines! https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehac237/6673929

Check out the new 2022 for CV Assessment and Management of Patients Undergoing https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehac270/6675076

trial: randomised trial in more than 21,000 patients with high blood pressure has concluded that protection against heart attack, stroke and vascular death is not affected by whether antihypertensive medications are taken in the morning or evening.

trial: polypill containing aspirin, atorvastatin and ramipril leads to clinically relevant reductions in recurrent events in post-myocardial infarction patients.

trial: sacubitril/valsartan does not change cognitive function, compared with valsartan, in patients with and mildly reduced or preserved ejection fraction.

New-onset atrial fibrillation is a major risk factor for stroke and death after transcatheter aortic valve replacement (TAVR) with the stroke risk concentrated in the first 30 days. This provides a window for monitoring and optimization of anti-thrombotics to minimize post-TAVR complications.

Learn more in : https://bit.ly/3LxGExB

Día mundial del corazón

Does age impact the safety and efficacy of ticagrelor monotherapy after percutaneous coronary intervention?

In this analysis from the TWILIGHT trial, ticagrelor monotherapy following 3 months of dual-antiplatelet therapy (DAPT) is associated with less bleeding compared to continued DAPT, with no increase in ischemic events, regardless of age.

Read more in : https://bit.ly/3ANeEkK